Cytotron® Delivered Rotational Field Quantum Nuclear Magnetic Resonance Therapy for Multiple Sclerosis

Multiple Sclerosis Clinical Trial

— RFQMR  

Official title:

Efficacy of Rotational Field Quantum Nuclear Magnetic Resonance (RFQMR) Based Tissue Engineering in the Treatment of Multiple Sclerosis

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT01220830
• Other study ID #: 100915_CIP_MS_V1.0
• Status: Active, not recruiting
• Phase: Phase 2
• First received: October 9, 2010
• Last updated: September 16, 2011
• Start date: September 2010
• Est. completion date: December 2011

Study information

• Verified date: September 2011
• Source: The Centre for Advanced Research & Development, India
• Contact: n/a
• Is FDA regulated: No
• Health authority: India: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to evaluate the efficacy of RFQMR therapy in remyelination in cases of Multiple sclerosis.

The evaluation will be done based on MRI findings, by clinical/ neurological examination and by assessment of quality of life before and after completion of therapy.

Description:

Transmembrane Potential (TMP) is one of the known cellular signalling pathways regulating synthesis of various proteins like those responsible for programmed cell death (e.g., p53 group) at the appropriate time in living cells. Many illnesses like cancer and degenerative diseases are linked to disturbances in transmembrane potential and protein transcription process.(Cone CD, 1970)

The protein responsible for production of myelin by the oligodendrocytes is Connexin 32. It has been established that in cases of Multiple Sclerosis (MS) this protein is not synthesized by the oligodendrocytes thus leading to non-repair of the demyelination process in the Central Nervous System (CNS) (Scherer SS et al., 1995; Sargiannidou I et al., 2009; Bondurand N et al., 2001). This causes the fibrotic damage and plaque formation and consequent signs and symptoms of MS. RFQMR therapy addresses this process of stimulation of Oligodendrocytes to synthesize Connexin 32 thus causing remyelination.

RFQMR therapy is delivered with CYTOTRON®. This device is a long body, wide bore machine with 864 guns, with near field antennae and parabolic reflector delivery system. The device is capable of producing a wide range of dosimetry, involving multiple modulations in both fixed and variable proton density dosimetry. Appropriately modulated multi-harmonic Radio Frequency (RF) signals in the lower end of the electromagnetic spectrum can be used in altering the cell signaling process using the TMP pathways, thus able to tackle systemic disorders. Generically known as Rotational Field Quantum Nuclear Magnetic Resonance (RFQMR), it is a technology that is made to deliver highly complex quantum instantaneous Nuclear Magnetic Resonance beams in the RF bands and its harmonics ranging from 3KHz to 300 MHz with a near field delivery using specialized antenna in the presence of high instantaneous magnetic field.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 40
• Est. completion date: December 2011
• Est. primary completion date: December 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• Male and female patients with clinically definite MS according to Polman

• Age 18 to 60 yrs.

• EDSS 0 to 7.

• Relapse-free > 30 days prior to inclusion.

• Stable immunomodulatory or immunosuppressive. therapy or treatment for > 3 months prior to inclusion.

• In case of treatment with antidepressants:

stable therapy > 3 months prior to inclusion.

• Highly effective methods of birth control for females.

Exclusion Criteria:

• Pregnancy

• Cardiac pacemakers, biostimulators, neurostimulators, cochlear implants, hearing aids.

• MRI incompatible implants like intramedullary nails, intracranial aneurysm clips, intra-orbital metal fragments, stents, implanted medication pumps etc near target area.

• Critically ill patients needing life support system.

• Mentally challenged patients who cannot give informed consent.

• Severely ill patients who cannot lie in supine position for 1 hour.

• H/o brain injury and/ or any malignant disorder

• Personal or family history of epilepsy / brain tumor.

• Relapse of MS < 30 days prior to inclusion

• Change of immunomodulatory therapy < 30 days prior to inclusion

• Bipolar disorder

• History of stroke or other brain lesions

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Multiple Sclerosis
• Sclerosis

Intervention

Device:
• Cytotron
Exposure to RFQMR with Cytotron for 28 consecutive days for one hour daily.

Locations

Country	Name	City	State
India	Centre for Advanced Research and Development	Bangalore	Karnataka

Sponsors (1)

Lead Sponsor	Collaborator
The Centre for Advanced Research & Development, India

Country where clinical trial is conducted

India, 

References & Publications (1)

Cone CD Jr. Variation of the transmembrane potential level as a basic mechanism of mitosis control. Oncology. 1970;24(6):438-70. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Effect of RFQMR therapy on MS lesion confirmed by Magnetic Resonance Imaging (MRI)	Change in number of T1 gadolinium- enhancing lesions on MRI from baseline to 90 days post therapy.; Change in number of lesions on FLAIR MRI images from baseline to 90 days post therapy.; Change in volume of five larger lesions of brain and spine from baseline to 90 days post therapy	Change from baseline to 90 days post therapy	No
Secondary	Effect of RFQMR therapy on disability status and quality of life of MS patients.	Change in Extended Disability Status Score (EDSS) from baseline to 90 days post therapy.; Change in Functional Assessment for Multiple sclerosis (FAMS) score from baseline to 90 days post therapy.	Change from baseline to 90 days post therapy	No